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CORRESPONDENCE
Breast Carcinoma During Pregnancy
International Recommendations from An Expert
Meeting
O ne of the recommendations from an expert meeting1 regardingbreast carcinoma treatment during pregnancy was that radia-
tion therapy should be delayed until after delivery. However, we
believe the authors have overestimated the risks of radiation
therapy.
The risks of irradiation have been reviewed previously by
the International Commission on Radiological Protection.2,3 In
general, the expected effects are malformations, a decrease in
intelligence, mental retardation (deterministic effects), and can-
cer induction. For deterministic effects, threshold doses of 0.2
gray (Gy) have been found. An estimate of the lifetime risk of
radiation-induced fatal cancer at 0.01 Gy is approximately
0.06%.
Maternal breast irradiation in the first 8 weeks of organogenesis
will expose the fetus to 0.05–0.15 Gy (the reference dose is 50 Gy).
Toward the end of pregnancy, the fetus lies closer to the radiation
field and could receive >1 Gy for the same treatment course.4 How-
ever, the fetal dose due to leakage radiation from the tube head of
the linear accelerator and scatter from collimator and blocks can be
reduced with a factor 2 to 4 by proper shielding.
Therefore, in the majority of cases, the radiation dose can be
kept below the threshold dose for deterministic effects. The risk of
radiation-induced cancer is low, and is negligible with a lifetime
risk, without irradiation, of approximately 1 in 3.
A review of successful radiation therapy for breast cancer (as
well as Hodgkin disease) with supplemental shielding during preg-
nancy was published recently.5
In summary, the recommendation not to irradiate a pregnant
patient until after birth is not tenable. Pregnancy is not a contrain-
dication to radiotherapy in patients with breast cancer and other
cancers that develop away from the pelvis.
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W e agree with Drs. Kal and Struikmans that therisk to the fetus during radiotherapy for supra-
diaphragmatic disease appears to be minimal, pro-
vided special attention is paid to the treatment
techniques and that the fetus is adequately shielded.1
Otherwise, the fetus could receive >1 gray (Gy) of
radiation, especially during the third trimes- ter when
the fetus lies closer to the radiation field.2
To keep the risk to a minimum, the general rec-
ommendation is to postpone radiotherapy until after
delivery.3 However, the need for immediate radio-
therapy in patients with breast carcinoma, in whom
it is usually postponed until after chemotherapy and
surgery have been completed, and those with Hodg-
kin disease is different.
In any case, this is a moot point because preg-
nancy lasts 40 weeks and surgery and chemotherapy
will be given before radiotherapy.
However, more information regarding treatment
recommendations and their acceptance should be
compiled in a registry study such as that of the Ger-
man Breast Group.4
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Distribution of Human
Papillomavirus Types in ThinPrep
Papanicolaou Tests Classified
According to the Bethesda 2001
Terminology and Correlations with
Patient Age and Biopsy Outcomes
T he sensitivity of the study by Evans et al. is dimin-ished by the detection of Grade III cervical intrae-
pithelial neoplasia despite an initial diagnosis sug-
gesting benign disease.1 More beneficial would be a
focus on identifying women age <30 years who are at
high risk. This is particularly important because this
group has been demonstrated to be more likely to be
infected with the oncogenic haplotypes of the human
papillomavirus (HPV) (e.g., HPV-16, HPV-51, and HPV-
53) believed to be responsible for both cervical and
anal malignancies.2 Women with cervical HPV infec-
tion have a 3-fold increased risk of concurrent anal
infection. There is an approximately 30% genotype-
specific concordance in the HPV haplotypes that cause
both anal and cervical cancers.3 Attempts to reduce
the financial costs of evaluating low-risk women are
offset by the ability to simultaneously screen for 2 can-
cers in high-risk women. Young females, many of
whom bear other risk factors for HPV infection (regular
use of alcohol, multiple sexual partners, a history of
chlamydial infection3) are increasingly becoming
infected at both sites, suggesting vaginal and anal
intercourse with the same infected partner(s). The
focus of the report by Evans et al.1 appears misguided
and out of touch with the contemporary epidemiologic
impact of HPV. A focus on the identification of young
females at a higher risk for oncogenic HPV infection
with an emphasis on expedient referral would allow
for a more meaningful clinical contribution.
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W e thank Dr. Hayanga for the interest in ourresearch, which we maintain is entirely relevant
to ‘‘contemporary epidemiology.’’1 To our knowledge,
the study is the first to examine the distribution
of human papillomavirus (HPV) types across the Be-
thesda 2001 diagnostic categories and allows an
holistic appreciation of the relationship between
HPV type and cytologic diagnosis, biopsy outcome,
and age. Currently, high-risk HPV testing by Hybrid
Capture 2TM assay (Digene Corporation, Gaithersburg,
MD) is recommended for patients with atypical squa-
mous cells of undetermined significance (ASCUS).2
Our data suggest that high-risk HPV testing, at least by
polymerase chain reaction, might also benefit the
management of patients with low-grade squamous
intraepithelial lesions (LSILs).
Dr. Hayanga’s comment that the sensitivity of
our study was diminished by the detection of Grade
III cervical intraepithelial neoplasia (CIN III) despite
an initial diagnosis suggestive of benign disease is
unclear; CIN III was not identified in our series after
a negative Papanicolaou (Pap) test, but rather was
detected only after abnormal cytology, and was re-
corded for a small minority of patients diagnosed
with ASCUS or LSIL.
Dr. Hayanga’s comments regarding anal carci-
noma testing are also unclear, because routine
screening is reserved for high-risk male and female
groups in large dedicated centers. In addition, the
management of preneoplastic anal lesions is contro-
versial, problematic, and fraught with the potential
for overtreatment.3
Any markers that help identify women at risk for
high-grade cervical disease are to be welcomed. How-
ever, the ‘‘behavioral’’ identifiers Dr. Hayanga appears
to suggest would require questionnaires from each
(young) patient undergoing a Pap test. Difficulties
in organizing the collection and processing of such
data aside, it is likely that most patients would be
uncomfortable providing details regarding multiple
sexual partners, anal intercourse, alcohol usage, infec-
tious diseases, etc. It is important to avoid any sense of
stigmatization that might deter women from partici-
pation in cervical screening programs.4
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